699 related articles for article (PubMed ID: 35342986)
1. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
[TBL] [Abstract][Full Text] [Related]
2. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
Ebrahimi M; Karami L; Alijanianzadeh M
Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
[TBL] [Abstract][Full Text] [Related]
3. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
Lee RK; Li TN; Chang SY; Chao TL; Kuo CH; Pan MY; Chiou YT; Liao KJ; Yang Y; Wu YH; Huang CH; Juan HF; Hsieh HP; Wang LH
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409412
[TBL] [Abstract][Full Text] [Related]
4. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
[TBL] [Abstract][Full Text] [Related]
5. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
[TBL] [Abstract][Full Text] [Related]
6. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation.
Fu L; Gilham D; Stotz SC; Sarsons CD; Rakai BD; Tsujikawa LM; Wasiak S; Johansson JO; Sweeney M; Wong NCW; Kulikowski E
Int Immunopharmacol; 2023 Apr; 117():109929. PubMed ID: 36857935
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 attachment to host cells is possibly mediated via RGD-integrin interaction in a calcium-dependent manner and suggests pulmonary EDTA chelation therapy as a novel treatment for COVID 19.
Dakal TC
Immunobiology; 2021 Jan; 226(1):152021. PubMed ID: 33232865
[TBL] [Abstract][Full Text] [Related]
8. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation.
Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD
J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988
[TBL] [Abstract][Full Text] [Related]
9. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2.
Wang WJ; Chen Y; Su WC; Liu YY; Shen WJ; Chang WC; Huang ST; Lin CW; Wang YC; Yang CS; Hou MH; Chou YC; Wu YC; Wang SC; Hung MC
J Food Biochem; 2022 Oct; 46(10):e14354. PubMed ID: 35894128
[TBL] [Abstract][Full Text] [Related]
10. Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.
Ramasamy S; Subbian S
Clin Microbiol Rev; 2021 Jun; 34(3):. PubMed ID: 33980688
[TBL] [Abstract][Full Text] [Related]
11. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
[TBL] [Abstract][Full Text] [Related]
12. Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein.
Beirag N; Varghese PM; Neto MM; Al Aiyan A; Khan HA; Qablan M; Shamji MH; Sim RB; Temperton N; Kishore U
Viruses; 2023 May; 15(6):. PubMed ID: 37376569
[TBL] [Abstract][Full Text] [Related]
13. Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.
Paidi RK; Jana M; Mishra RK; Dutta D; Pahan K
J Immunol; 2021 Nov; 207(10):2521-2533. PubMed ID: 34645689
[TBL] [Abstract][Full Text] [Related]
14. A potential antiviral activity of Esculentoside A against binding interactions of SARS-COV-2 spike protein and angiotensin converting enzyme 2 (ACE2).
Zeng MS; Yu WD; Wang HX; Liu JY; Xu PP
Int J Biol Macromol; 2021 Jul; 183():2248-2261. PubMed ID: 34111482
[TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
16. Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2.
Uhomoibhi JO; Shode FO; Idowu KA; Sabiu S
J Mol Graph Model; 2022 Jul; 114():108185. PubMed ID: 35430474
[TBL] [Abstract][Full Text] [Related]
17. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
18. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
19. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
20. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
